Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.625
Bid: 0.60
Ask: 0.65
Change: -0.025 (-3.85%)
Spread: 0.05 (8.333%)
Open: 0.65
High: 0.65
Low: 0.625
Prev. Close: 0.65
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Parsley Box to exit AIM as shares wilt since IPO

Fri, 18th Nov 2022 11:16

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Parlsey Box Group PLC, up 43% at 2.36 pence, 12-month range 1.2p-47.74p. The Edinburgh-based meal delivery firm proposes to re-register as a private limited company as it sets December 14 as date for a general meeting to vote on the plan. At the general meeting next month, the proposal needs 75% approval of votes cast by shareholders. Parsley Box says it has received irrevocable undertakings representing about 36% of the company's issued share capital to vote in favour of going private. The firm only started trading publicly on London's AIM in March 2021 with a placing price of 200 pence per share.

----------

MyHealthChecked PLC, up 15% at 1.84p, 12-month range 1.1p-3.8p. The Cardiff-based healthcare company proposes a capital reduction, to be voted on at a general meeting on December 6. It seeks shareholder approval to cancel its share premium account and capital redemption reserve, as well as to cancel deferred shares. This would "eliminate [its] retained losses and create distributable reserves equal to the balance", it says. Its current negative distributable reserves position means it is currently unable to declare dividends or buy back its shares. A resolution would grant it authority to purchase up to 78 million of its ordinary shares, which is around 10% of its share capital, which it would intend to cancel. A court hearing to confirm the capital reduction is expected on January 17 next year.

----------

AIM - LOSERS

----------

Eco Atlantic Oil & Gas Ltd, down 54% at 19.15p, 12-month range 17p-46p. The stock nears a 12-month low as the oil and gas explorer says that its Gazania-1 well had reached its target depth of 2,360 metres but did not show evidence of commercial hydrocarbons. The well, which was spudded on October 10, will now be plugged and abandoned. "While it is naturally disappointing not having made a commercial discovery, the Gazania-1 well was only the first of four wells we have planned for the next 18-24 months across our wider portfolio," says Gil Holzman, co-founder & chief executive officer of Eco Atlantic. The company will now move onto executing plans for more exploration wells.

----------

N4 Pharma PLC, down 27% at 2.05p, 12-month range 1.51p-8.69p. The Derby, England-based pharmaceutical company raises GBP1 million in placing of 50.0 million shares at an issue price of 2p. Also launches broker offer for an initial expected value of GBP250,000 at the same price. Says net proceeds will be used to progress its development work "relating to the loading of SiRNA onto Nuvec, including to commit to doing in-vivo studies and also to explore acquisition opportunities".

----------

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
14 Sep 2020 10:52

N4 Pharma Plunges 40% As Covid-19 Antibody Delivery Study Disappoints

N4 Pharma Plunges 40% As Covid-19 Antibody Delivery Study Disappoints

Read more
14 Sep 2020 09:04

N4 Pharma plunges as Covid-19 progress stalls

(Sharecast News) - N4 Pharma lost more than a third of its value after the company said its potential Covid-19 vaccine delivery method did not produce a positive result at stage 3 of tests.

Read more
1 Sep 2020 21:35

IN BRIEF: N4 Pharma Signs Technology Transfer & Manufacturing Contract

IN BRIEF: N4 Pharma Signs Technology Transfer & Manufacturing Contract

Read more
1 Sep 2020 09:19

N4 Pharma chooses Ardena as contract manufacturing partner

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has appointed the API and nanomedicines business unit of Ardena as its contract development and manufacturing organisation partner for the technology transfer and upscaling manufacture of 'Nuvec', it announced on Tuesday.

Read more
12 Aug 2020 14:18

N4 Pharma Shares Spike 30% On Successful Covid-19 Study

N4 Pharma Shares Spike 30% On Successful Covid-19 Study

Read more
6 Jul 2020 14:13

IN BRIEF: N4 Pharma's Nuvec Shows Promise In Oral Vaccine Delivery

IN BRIEF: N4 Pharma's Nuvec Shows Promise In Oral Vaccine Delivery

Read more
28 May 2020 14:49

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

Read more
28 May 2020 09:47

N4 Pharma completes first stage proof of concept work for Nuvec

(Sharecast News) - Pharmaceutical group N4 Pharma has completed the first phase of Covid-19 proof of concept work for Nuvec, the group's novel delivery system for cancer treatments and vaccines.

Read more
18 May 2020 15:39

N4 Pharma To File Nuvec Patent Across Europe, US, Other Major Markets

N4 Pharma To File Nuvec Patent Across Europe, US, Other Major Markets

Read more
13 May 2020 14:55

N4 Pharma Raises GBP2 Million To Fund Covid-19 Research Project

N4 Pharma Raises GBP2 Million To Fund Covid-19 Research Project

Read more
13 May 2020 11:30

N4 Pharma raises ?2.03m via oversubscribed placing

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has raised ?2.03m through an oversubscribed placing of 50,731,250 new ordinary shares, it announced on Wednesday, at a price of 4p each.

Read more
24 Apr 2020 14:33

N4 Pharma Files Patent For Nuvec Opportunities In Viral Vector Market

N4 Pharma Files Patent For Nuvec Opportunities In Viral Vector Market

Read more
24 Apr 2020 09:30

N4 Pharma files for new UK patent on 'Nuvec'

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has filed a new UK patent application around both the ability of its 'Nuvec' delivery system ability to be used to manufacture viral vectors, and to make viral vectors more efficient in applications such as ex-vivo gene therapy treatments.

Read more
16 Apr 2020 15:59

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
16 Apr 2020 14:57

UK TRADING UPDATE SUMMARY: NHS Uses Induction Healthcare's Mobile App

UK TRADING UPDATE SUMMARY: NHS Uses Induction Healthcare's Mobile App

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.